Anne Marie Conway, M.H.A., R.N. is Senior Vice President of Clinical Development and Program Management at Skylark Bio. Anne Marie brings 30+ years of experience in clinical drug development with demonstrated success through optimizing clinical program outcomes through all phases of product lifecycle management. Her career trajectory has taken her from academia to industry where she has held roles of increasing responsibility in clinical development, clinical operations, and program management.

Most recently, Anne Marie was a consultant to Myrtelle Gene Therapies where she was Acting Head of Clinical Operations. Other roles in gene therapy have included Clinical Head of Biologics at PTC Therapeutics and Vice President of Clinical Operations at Agilis Biotherapeutics. While at Agilis and then at PTC, Anne Marie was the Clinical Lead for the AADC AAV gene therapy program resulting in the approval of Upstaza™ in the UK and Europe.

Her other roles have included Vice President and Program Executive for Autism Spectrum Disorder and Vice President of Clinical Operations at Finch Therapeutics. Prior to that she was Vice President Clinical Development Operations at Shire Human Genetic Therapies. While at Shire HGT, Anne Marie led a global organization of 80+ people and was involved in 4 product approvals, including elaprase™ for the treatment of Hunter syndrome.

Prior to making the transition to the biotech industry, Anne Marie was the Research Manager for the Gastroenterology Division at Tufts Medical Center in Boston.

Anne Marie is currently a Senior Lecturer (Adjunct) in Healthcare Administration at Suffolk University in the Sawyer Business School where she teaches graduate level courses in Innovation and Strategic Management.

Anne Marie received her Bachelor of Science with a major in Nursing from Boston University and a Master of Health Administration from Suffolk University.